These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31703009)

  • 1. Examining the Causes and Consequences of Increasing Insulin Costs With Prospective Interventions.
    Dawkins M; Menon T; Myers AK
    Am J Ther; 2020; 27(1):e115-e120. PubMed ID: 31703009
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of biosimilar manufacturers in improving access to insulin globally.
    Perrin C; Ewen M; Beran D
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):578. PubMed ID: 28629907
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of biosimilar insulins on the diabetes landscape.
    White J; Wagner A; Patel H
    J Manag Care Spec Pharm; 2022 Jan; 28(1):91-98. PubMed ID: 34726499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar insulin could offer patients cost-saving options.
    Karlovitch S
    Am J Manag Care; 2019 Sep; 25(10 Spec No.):. PubMed ID: 31860243
    [No Abstract]   [Full Text] [Related]  

  • 5. Bullying biosimilars: cheaper drugs stymied in USA.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
    [No Abstract]   [Full Text] [Related]  

  • 6. Biosimilars-Curb Your Enthusiasm.
    Yang YT; Chen B; Bennett CL
    JAMA Oncol; 2017 Nov; 3(11):1467-1468. PubMed ID: 28594963
    [No Abstract]   [Full Text] [Related]  

  • 7. Pfizer-Allergan deal could reduce biosimilar cost savings.
    Johnson SR
    Mod Healthc; 2015 Dec; 45(49):12. PubMed ID: 26875340
    [No Abstract]   [Full Text] [Related]  

  • 8. Biosimilar Insulin and Costs: What Can We Expect?
    Heinemann L
    J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars for insulin: a cost-saving alternative?
    McCall C
    Lancet; 2018 Aug; 392(10146):463-464. PubMed ID: 30129449
    [No Abstract]   [Full Text] [Related]  

  • 10. The Insulin Boom. WHY THE COST OF THIS LIFESAVING DRUG IS REACHING NEW HEIGHTS.
    Tsai A
    Diabetes Forecast; 2016; 69(2):32-7. PubMed ID: 27048046
    [No Abstract]   [Full Text] [Related]  

  • 11. Basaglar, an Insulin 'Follow On,' Prepares To Do Battle With Lantus.
    Reinke T
    Manag Care; 2017 Apr; 26(4):12-14. PubMed ID: 28511765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotech innovators jump on biosimilars bandwagon.
    Moran N
    Nat Biotechnol; 2012 Apr; 30(4):297-9. PubMed ID: 22491261
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of Devices in Insulin Delivery.
    Meneghini LF; McNulty JN
    Diabetes Technol Ther; 2017 Feb; 19(2):76-78. PubMed ID: 28118052
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market.
    Levy J; Chowdhury ZM; Socal MP; Trujillo AJ
    JAMA Intern Med; 2021 Oct; 181(10):1405-1407. PubMed ID: 34180955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar insulin and insulin antibodies.
    Heinemann L; Owens D
    J Diabetes Sci Technol; 2013 Jul; 7(4):806-7. PubMed ID: 23911160
    [No Abstract]   [Full Text] [Related]  

  • 16. Limited distribution networks stifle competition in the generic and biosimilar drug industries.
    Karas L; Shermock KM; Proctor C; Socal M; Anderson GF
    Am J Manag Care; 2018 Apr; 24(4):e122-e127. PubMed ID: 29668215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
    Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
    Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The High Cost of Insulin in the United States: An Urgent Call to Action.
    Rajkumar SV
    Mayo Clin Proc; 2020 Jan; 95(1):22-28. PubMed ID: 31902423
    [No Abstract]   [Full Text] [Related]  

  • 19. Business of biosimilars - 14th annual conference (October 15-17, 2013 - Boston, Massachusetts, USA).
    Bourgoin A
    Drugs Today (Barc); 2013 Dec; 49(12):799-801. PubMed ID: 24524098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fate of cost-saving biosimilar drugs may hinge on naming policy.
    Johnson SR
    Mod Healthc; 2016 Aug; 45(27):7, 9. PubMed ID: 30387953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.